ReCor Medical Presents RADIANCE Clinical Trial Program Results of Paradise Ultrasound Renal Denervation System for Hypertension at AHA 2022
Shots:
- The pooled data from RADIANCE Program consist 3 trials i.e., (RADIANCE-HTN TRIO) in patients with resistant hypertension & (RADIANCE-HTN SOLO) and (RADIANCE II) in mild-mod. hypertension evaluated endovascular Paradise uRDN System in 500+ patients
- The trials met their primary efficacy EPs with statistical significance @2mos., 50% achieved reduction in daytime ambulatory systolic BP with ≥10mmHg decrease @2mos., BP results were similarly positive in the 24hr., nighttime, home, and office measures. The safety profile was consistent across the studies
- 25% reduction in cardiovascular risk in a meta-analysis of the CV benefits of antihypertensive medications. The system achieved a CE mark for hypertension in the EU
Ref: Businesswire | Image: ReCor Medical
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
